ÂÜÀòÂÒÂ×

Karla Gregory, MBA, MSF has extensive experience in financial planning and analysis roles. Karla is currently the Director of Financial Planning and Analysis at Cogent Biosciences, a position they have held since June 2021. Prior to this, they served as the Director, FP&A at X4 Pharmaceuticals from December 2019 to June 2021.

From August 2018 to December 2019, Karla worked as the Director, FP&A at Genocea, where they led finance support across various immunotherapy programs. Before that, they were the Sr. Finance Manager at Radius Health, Inc. from July 2016 to August 2018, providing strategic and analytical finance support for osteoporosis and breast cancer R&D programs.

In their previous roles, Karla held finance positions at Shire Pharmaceuticals, Fresenius Medical Care, Genzyme, and PTC, where they gained experience in financial planning, analysis, and budgeting. Karla also worked at Brigham and Women's Hospital, Department of OB/GYN, as a Senior Financial Analyst, where they managed budgeting, forecasting, and planning activities.

Karla's expertise lies in financial planning and analysis, budgeting, forecasting, and variance analysis. Karla has a strong track record of providing strategic financial support and influencing decision-making across various functional and departmental teams.

Karla Gregory, MBA, MSF, completed their Bachelor of Arts degree in Psychology & Biology at Boston University from 1995 to 1999. Afterward, they pursued further education at the D'Amore-McKim School of Business at Northeastern University, where they earned their Master of Business Administration (MBA) and Master of Science in Finance (MSF) from 2005 to 2009. Their area of focus during their studies at Northeastern University was in Corporate Finance and Investments.